Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.56 |
| ▸ | ECE1 | P42892 | 3/20 | 0.55 |
| ▸ | MME | P08473 | 2/20 | 0.55 |
| ▸ | CETP | P11597 | 3/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.52 |
| ▸ | CTSS | P25774 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.50 |
| ▸ | ITGAV | P06756 | 2/20 | 0.50 |
| ▸ | TGM2 | P21980 | 2/20 | 0.48 |
| ▸ | KYNU | Q16719 | 1/20 | 0.48 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1111237 | 0.88 | SIRT2 (0.54) | SIRT2SIRT1ECE1MMECTSL | |
| SCHEMBL1111300 | 0.88 | SIRT2 (0.54) | SIRT2SIRT1ECE1MMECTSL | |
| SCHEMBL1111240 | 0.88 | SIRT2 (0.54) | SIRT2SIRT1ECE1MMECTSL | |
| SCHEMBL13530114 | 0.87 | ECE1 (0.57) | SIRT2SIRT1ECE1MMECTSL | |
| SCHEMBL3171832 | 0.87 | ECE1 (0.57) | SIRT2SIRT1ECE1MMECTSL | |
| SCHEMBL1111109 | 0.85 | SIRT2 (0.53) | SIRT2SIRT1ECE1MMECTSL | |
| SCHEMBL1111167 | 0.85 | SIRT2 (0.53) | SIRT2SIRT1ECE1MMECTSL | |
| SCHEMBL1111112 | 0.85 | SIRT2 (0.53) | SIRT2SIRT1ECE1MMECTSL | |
| SCHEMBL8387978 | 0.84 | FOLH1 (0.65) | SIRT2SIRT1ECE1CTSLCTSS | |
| SCHEMBL8848864 | 0.83 | SIRT2 (0.62) | SIRT2SIRT1ECE1MMECTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | SIRT2 3197/4885SIRT1 3020/4885ECE1 2821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.